Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.

Last update: Oct 18, 2024

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) was identified as an affordable growth stock by our stock screener. NASDAQ:BMRN is showing great growth, but also scores well on profitability, solvency and liquidity. At the same time it seems to be priced reasonably. We'll explore this a bit deeper below.

Growth Assessment of NASDAQ:BMRN

Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:BMRN boasts a 7 out of 10:

The Earnings Per Share has grown by an impressive 171.15% over the past year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.84%.
The Revenue has been growing by 10.16% on average over the past years. This is quite good.
BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.08% yearly.
The Revenue is expected to grow by 11.86% on average over the next years. This is quite good.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Deciphering NASDAQ:BMRN's Valuation Rating

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:BMRN scores a 7 out of 10:

94.69% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 94.87% of the companies in the same industry.
Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 94.69% of the companies in the same industry.
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 65.82% in the coming years.

What does the Health looks like for NASDAQ:BMRN

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:BMRN, the assigned 5 reflects its health status:

An Altman-Z score of 5.24 indicates that BMRN is not in any danger for bankruptcy at the moment.
BMRN has a better Altman-Z score (5.24) than 79.11% of its industry peers.
BMRN has a Debt to FCF ratio of 5.12. This is amongst the best in the industry. BMRN outperforms 94.69% of its industry peers.
BMRN has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
A Current Ratio of 3.05 indicates that BMRN has no problem at all paying its short term obligations.

Profitability Examination for NASDAQ:BMRN

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:BMRN has earned a 7 out of 10:

BMRN's Return On Assets of 3.63% is amongst the best of the industry. BMRN outperforms 94.51% of its industry peers.
BMRN has a Return On Equity of 4.85%. This is amongst the best in the industry. BMRN outperforms 94.69% of its industry peers.
BMRN has a better Return On Invested Capital (3.66%) than 94.51% of its industry peers.
The Profit Margin of BMRN (9.91%) is better than 95.58% of its industry peers.
BMRN has a better Operating Margin (10.73%) than 95.04% of its industry peers.
BMRN's Gross Margin of 80.07% is amongst the best of the industry. BMRN outperforms 87.26% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

Our latest full fundamental report of BMRN contains the most current fundamental analsysis.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.